Concepedia

Hong Xiang

HX

30

Publications

1.7K

Citations

23

H-Index

2001

Active since

Affiliations

GlaxoSmithKline (United States)(Current)

Five Prime Therapeutics (United States)

South Texas Accelerated Research Therapeutics

Sarah Cannon

University of California, Los Angeles

Hong Xiang is an author at GlaxoSmithKline (United States) specializing in medicine, pharmacology, and immunology.

ORCID

Top concepts

Publications per year

2001–2022

30

Publications

30

Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent

Mark Merchant, Xiaolei Ma, Henry R. Maun et al. · Proceedings of the National Academy of Sciences · 2013 · 239 citations · Full text

Genome-Wide Sequence Characterization and Expression Analysis of Major Intrinsic Proteins in Soybean (Glycine max L.)

Da Yong Zhang, Zulfiqar Ali, Chang Biao Wang et al. · PLoS ONE · 2013 · 146 citations · Full text

Effects of Anti-VEGF Treatment Duration on Tumor Growth, Tumor Regrowth, and Treatment Efficacy

Anil Bagri, Leanne Berry, Bert Gunter et al. · Clinical Cancer Research · 2010 · 134 citations

Discovery of GSK1070916, a Potent and Selective Inhibitor of Aurora B/C Kinase

Nicholas D. Adams, Jerry L. Adams, Joelle L. Burgess et al. · Journal of Medicinal Chemistry · 2010 · 108 citations · Full text

, , +21

Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma

Daniel V.T. Catenacci, Drew Rasco, Jeeyun Lee et al. · Journal of Clinical Oncology · 2020 · 99 citations · Full text

Rows per page

1–5 of 30